Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Visceral leishmaniasis (VL) is fatal if not treated and is prevalent widely in the tropical and sub-tropical regions of world. VL is caused by the protozoan parasite Leishmania donovani or Leishmania infantum. Although several second generation vaccines have been licensed to protect dogs against VL, there are no effective vaccines against human VL [1]. Since people cured of leishmaniasis develop lifelong protection, development of live attenuated Leishmania parasites as vaccines, which can have controlled infection, may be a close surrogate to leishmanization. This can be achieved by deletion of genes involved in the regulation of growth and/or virulence of the parasite. Such mutant parasites generally do not revert to virulence in animal models even under conditions of induced immune suppression due to complete deletion of the essential gene(s). In the Leishmania life cycle, the intracellular amastigote form is the virulent form and causes disease in the mammalian hosts. We developed centrin gene deleted L. donovani parasites that displayed attenuated growth only in the amastigote stage and were found safe and efficacious against virulent challenge in the experimental animal models. Thus, targeting genes differentially expressed in the amastigote stage would potentially attenuate only the amastigote stage and hence controlled infectivity may be effective in developing immunity. This review lays out the strategies for attenuation of the growth of the amastigote form of Leishmania for use as live vaccine against leishmaniasis, with a focus on visceral leishmaniasis.
Institute of Molecular Medicine, New Delhi, India. Electronic address: selvapandiyan@immindia.org.
Angamuthu
A
Selvapandiyan
Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Bethesda, MD, USA.
Ranadhir
R
Dey
Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Bethesda, MD, USA.
Sreenivas
S
Gannavaram
Institute of Molecular Medicine, New Delhi, India; C.G. Bhakta Institute of Biotechnology, Tarsadi, Gujarat, India.
Sumit
S
Solanki
National Institute of Pathology (ICMR), New Delhi, India.
Poonam
P
Salotra
Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Bethesda, MD, USA.
Hira L
HL
Nakhasi
D000818:Animals; D055786:Gene Knockout Techniques; D006801:Humans; D007893:Leishmania donovani / Q000235:genetics / Q000254:growth & development*; D018314:Leishmania infantum / Q000235:genetics / Q000254:growth & development*; D054332:Leishmaniasis Vaccines / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000276:immunology
D054332:Leishmaniasis Vaccines; D014613:Vaccines, Attenuated
Amastigote; Cell division; Centrin; Gene knockout; Leishmania; Vaccine; Visceral leishmaniasis